Literature DB >> 6208612

Diagnostic potential for human malignancies of bacterially produced HTLV-I envelope protein.

K P Samuel, J A Lautenberger, C L Jorcyk, S Josephs, F Wong-Staal, T S Papas.   

Abstract

Two regions of the gene for the human T-cell leukemia virus subgroup I (HTLV-I) envelope were expressed in Escherichia coli by use of the vector pJLA16. One corresponds to the carboxyl terminal region of the major envelope protein p46, and the other corresponds to the transmembrane protein p21E. Reactivity of the expressed protein with human serum was tested by the Western blot procedure. Each of 11 sera tested that had been shown to contain antibodies to HTLV-I or HTLV-II by an enzyme-linked immunosorbent assay recognized the bacterially synthesized envelope proteins. There was no reaction detected when 17 control sera were tested. This system will be useful for large-scale seroepidemiological surveys for HTLV-I and related human retroviruses.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6208612     DOI： 10.1126/science.6208612

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  10 in total

1.  Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

Authors:  L D Papsidero; R P Dittmer; L Vaickus; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

2.  Prevalence of human T-lymphotropic virus in civilian applicants for the United States Armed Forces.

Authors:  C R Roberts; D R Fipps; J F Brundage; S E Wright; M Goldenbaum; S S Alexander; D S Burke
Journal:  Am J Public Health       Date:  1992-01       Impact factor: 9.308

3.  Analysis of equine humoral immune responses to the transmembrane envelope glycoprotein (gp45) of equine infectious anemia virus.

Authors:  Y H Chong; J M Ball; C J Issel; R C Montelaro; K E Rushlow
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

4.  A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.

Authors:  J Arp; M LeVatte; J Rowe; S Perkins; E King; C Leystra-Lantz; S K Foung; G A Dekaban
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people.

Authors:  Y M Chen; T H Lee; K P Samuel; A Okayama; N Tachibana; I Miyoshi; T S Papas; M Essex
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

6.  Development and evaluation of a human T-cell leukemia virus type I serologic confirmatory assay incorporating a recombinant envelope polypeptide.

Authors:  E P Lillehoj; S S Alexander; C J Dubrule; S Wiktor; R Adams; C C Tai; A Manns; W A Blattner
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

7.  Novel Genetic Constructs for Production of Recombinant HTLV-1/2 Antigens and Evaluation of Their Reactivity to Plasma Samples from HTLV-1-Infected Patients.

Authors:  Ueriton Dias de Oliveira; Fred Luciano Neves Santos; Bernardo Galvão-Castro; Marco Aurelio Krieger; Nilson Ivo Tonin Zanchin
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

8.  Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals.

Authors:  R B Lal; W Heneine; D L Rudolph; W B Present; D Hofhienz; T M Hartley; R F Khabbaz; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

9.  Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.

Authors:  T J Palker; E R Riggs; D E Spragion; A J Muir; R M Scearce; R R Randall; M W McAdams; A McKnight; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

10.  Sensitivity and specificity of a recombinant transmembrane glycoprotein (rgp21)-spiked western immunoblot for serological confirmation of human T-cell lymphotropic virus type I and type II infections.

Authors:  R B Lal; S Brodine; J Kazura; E Mbidde-Katonga; R Yanagihara; C Roberts
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.